0001192482-13-000219.txt : 20131211
0001192482-13-000219.hdr.sgml : 20131211
20131211181107
ACCESSION NUMBER: 0001192482-13-000219
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131211
FILED AS OF DATE: 20131211
DATE AS OF CHANGE: 20131211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP
CENTRAL INDEX KEY: 0001361248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-889-9900
MAIL ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Woody James N.
CENTRAL INDEX KEY: 0001553355
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36208
FILM NUMBER: 131271979
MAIL ADDRESS:
STREET 1: C/O ONCOMED PHARMACEUTICALS, INC.
STREET 2: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
3
1
edgar.xml
PRIMARY DOCUMENT
X0206
3
2013-12-11
0
0001361248
TETRALOGIC PHARMACEUTICALS CORP
TLOG
0001553355
Woody James N.
C/O TETRALOGIC PHARMACEUTICALS CORP
343 PHOENIXVILLE PIKE
MALVERN
PA
19355
1
0
0
0
Series B Convertible Preferred Stock
Common Stock
354663
I
Directly owned by LVP Life Science Ventures III, L.P
Series B Convertible Preferred Stock
Common Stock
17733
I
Directly owned by LVP III Associates, L.P.
Series B Convertible Preferred Stock
Common Stock
8866
I
Directly owned by LVP III Partners, L.P.
Series C Convertible Preferred Stock
Common Stock
227266
I
Directly owned by LVP Life Sciences Ventures III, L.P.
Series C Convertible Preferred Stock
Common Stock
11363
I
Directly owned by LVP III Associates, L.P.
Series C Convertible Preferred Stock
Common Stock
5681
I
Directly owned by LVP Partners III, L.P.
Common Stock Warrants
.85
Common Stock
3475
I
Directly owned by LVP Life Sciences Ventures III, L.P.
Common Stock Warrants
.85
Common Stock
174
I
Directly owned by LVP III Associates, L.P.
Common Stock Warrants
.85
Common Stock
87
I
Directly owned by LVP III Partners, L.P.
Common Stock Warrants
.85
Common Stock
4170
I
Directly owned by LVP Life Sciences Ventures III, L.P.
Common Stock Warrants
.85
Common Stock
208
I
Directly owned by LVP III Associates, L.P.
Common Stock Warrants
.85
Common Stock
104
I
Directly owned by LVP III Partners, L.P.
Convertible Notes
Common Stock
I
Directly owned by LVP Life Science Ventures III, L.P.
Convertible Notes
Common Stock
I
Directly owned by LVP III Associates, L.P.
Convertible Notes
Common Stock
I
Directly owned by LVP III Partners, L.P.
Series C Warrants
6.4022
Common Stock
I
Directly owned by LVP Life Science Ventures III, L.P.
Series C Warrants
6.4022
Common Stock
I
Directly owned by LVP III Associates, L.P.
Series C Warrants
6.4022
Common Stock
I
Directly owned by LVP III Partners, L.P.
The Series B Convertible Preferred Stock will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and has no expiration date.
The Series C Convertible Preferred Stock will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and has no expiration date.
The warrants are immediately exercisable. The warrants expire on the later of 11/25/2019 or five years after the consummation of the Company's initial public offering.
The warrants are immediately exercisable. The warrants expire on the later of 03/10/2020 or five years after the consummation of the Company's initial public offering.
The Convertible Notes will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and have no expiration date.
Warrants will be automatically exercised immediately prior to the closing of the Issuer's initial public offering. Warrants are exercisable for a number of shares of common stock equal to the warrant amount divided by the exercise price and will be net exercised at the initial public offering price.
The reported securities are owned directly by each of LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates"), and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates, and Partners. The reporting person, a member of GP III, shares voting and investment power with respect to these shares but disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
James N. Woody
2013-12-11